Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
News|Articles|September 1, 2024
- Pharmaceutical Technology, September 2024
- Volume 48
- Issue 9
- Pages: 10
Virus Removal Filters
Author(s)Pharmaceutical Technology Editors
Asahi Kasei Medical now offers its Planova virus removal filters for use in biopharma manufacturing and plasma derivatives manufacturing.
Asahi Kasei Medical’s Planova virus removal filters are used in the manufacturing processes of biopharmaceuticals and plasma derivatives. The filters are also used in biosafety testing services and biopharmaceutical contract development and manufacturing operations. Planova comprises cellulose hollow-fiber membrane filters that were developed to specifically remove viruses from biotherapeutic products. The line was launched in 1989 and was followed by Planova BioEX hydrophilic polyvinylidene fluoride hollow-fiber membrane filters in 2009. Both product lines have been adopted worldwide. The latest offering is Planova S20N, a next-generation line of cellulose hollow-fiber membrane filters, which was launched in 2022. This latest addition features robust virus removal capability and simplified operation.
Articles in this issue
about 2 years ago
Understanding the Value of Excipient Gradeabout 2 years ago
Determining Low PPB Levels of Nitrite in Polymeric Excipientsabout 2 years ago
Molecular Modeling in Formulation Developmentabout 2 years ago
Advancing Robotic Automationabout 2 years ago
Meeting Adventitious Agent Testing Needs for Complex Modalitiesabout 2 years ago
It’s All About the Small Thingsabout 2 years ago
Responding to Mpoxabout 2 years ago
Strategic Decarbonizationabout 2 years ago
Keeping Audit and Inspection Programs Currentabout 2 years ago
European Artificial Intelligence Act Comes into ForceRelated to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.